Mantle Cell Lymphoma | Topics

 
Treatment at Academic Treatment Centers Appears to Yield Longer Survival in Mantle Cell Lymphoma
January 11, 2022

Patients with mantle cell lymphoma treated in academic facilities appeared to have a longer overall survival compared those treated at with non-academic centers.

Study Design Confirmed for Phase 3 Trial of Zilovertamab/Ibrutinib in Mantle Cell Lymphoma
January 06, 2022

A design for the phase 3 ZILO-301 clinical trial, assessing the efficacy of zilovertamab plus ibrutinib for patients with mantle cell lymphoma, has been selected

Early Relapse Appears Predictive of OS Outcomes in Mantle Cell Lymphoma
December 23, 2021

Early relapsed appears to be an important predictor of survival among patients with mantle cell lymphoma.

Previously Treated MCL Resistant to Ibrutinib and Venetoclax May Respond to Pirtobrutinib
December 12, 2021

Preclinical data show promise for the novel non-covalent Bruton tyrosine kinase inhibitor pirtobrutinib in mantle cell lymphoma with resistance to both ibrutinib and venetoclax.

Pre-treatment HRQOL Prognostic Factors Identified for Older Patients With Newly Diagnosed Mantle Cell Lymphoma
December 04, 2021

Researchers utilized the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire to examine the prognostic impact on survival of pre-treatment health-related quality of life parameters for patients with newly diagnosed mantle cell lymphoma.

Promising Efficacy and Safety Profile Seen With Concurrent Ibrutinib and Venetoclax for R/R Mantle Cell Lymphoma
November 19, 2021

Phase 3 data suggest that concurrent treatment with ibrutinib and venetoclax yielded promising efficacy for patients with relapsed/refractory mantle cell lymphoma.

NDA for Parsaclisib Receives FDA Priority Review in MCL and MZL
November 02, 2021

The FDA granted priority review to a new drug application for parsaclisib in patients with mantle cell lymphoma and other non-Hodgkin lymphomas.

Yazeed Sawalha, MD, on Use of Autologous Stem Cell Transplant in Mantle Cell Lymphoma
October 31, 2021

Yazeed Sawalha, MD, discusses how often autologous stem cell transplant is utilized in patients with mantle cell lymphoma.

Yazeed Sawalha, MD, on How Socioeconomic Factors May Impact Completion of ASCT and Clinical Outcomes in MCL
October 29, 2021

Yazeed Sawalha, MD, discusses how socioeconomic factors may impact the completion of autologous stem cell transplant in patients with mantle cell lymphoma, as well as impacting clinical outcomes.

Sawalha Examines the Impact of Socioeconomic Factors on the Use of Autologous Stem Cell Transplant in MCL
October 18, 2021

In an interview with CancerNetwork, Yazeed Sawalha, MD, discussed how socioeconomic factors can affect use of autologous stem cell transplant in multiple myeloma and lead to disparities.